We assessed the penetration of a new carbapenem antibiotic, meropenem, into abdominal tissues. A single 1,000-mg intravenous dose was administered to 66 patients undergoing elective intraabdominal surgery. Plasma, body fluid (peritoneal fluid and bile), and tissue samples (colon, gallbladder, omentum, stomach, fascia, muscle, and skin) were taken at various times up to 8 hours after administration of the dose. Meropenem concentrations were determined by means of validated bioassay techniques. Peak meropenem concentrations in most tissue specimens and one body fluid occurred within -1 hour; the exceptions were bile and muscle specimens, in which peak concentrations were present in -2 to -4 hours. The bile concentration increased with time, thus indicating active excretion of drug into bile. Only one adverse event (mild nausea) was attributable to meropenem. Our results show that meropenem achieves adequate tissue concentrations for the treatment of intraabdominal infections due to susceptible bacteria.
intraabdominal surgery following administration of a single intravenous dose of the drug.
Methods
Hospitalized adult patients who were scheduled to undergo elective intraabdominal operations were enrolled in this multicenter, open-label trial. The Institutional Review Board at each center approved the study, and all patients gave written informed consent before enrollment. A single 1,000-mg dose of meropenem (supplied by Zeneca Pharmaceuticals Group, Wilmington, DE) was administered just before the start of each operation by intravenous infusion over 30 minutes.
Tissue and body fluid samples were obtained at one of four intervals after the start of meropenem infusion: -1 hour (30 minutes to 1 hour and 30 minutes), -2 hours (1 hour and 31 minutes to 3 hours), -4 hours (3 hours and 1 minute to 5 hours), or -6 hours (5 hours and 1 minute or longer). Plasma samples were obtained before the administration of meropenem, at the time that the first tissue or other fluid sample was obtained, and frequently again after the last tissue or other fluid sample was obtained. The types of tissue samples varied with the surgical procedure performed. Samples were stored at -70°C to -80°C until they were analyzed. Before analysis, tissue samples were weighed, suspended in 2.5 vol of cold 1% phosphate buffer (pH 6), and homogenized for 30 to 60 seconds at high speed by using a hand-held blender. Cell debris was removed by means of brief low-speed centrifugation.
Routine prophylactic antibiotics were not given until after all samples were obtained. Prophylactic oral doses of erythromycin and neomycin were permitted since preliminary tests demonstrated that these antibiotics do not interfere with the determination of meropenem concentrations in tissue (data on file, Zeneca Pharmaceuticals Group). The lack of interference by erythromycin or neomycin on the bioassay for meropenem concentrations was determined by adding solutions of these drugs singly and in combination to solutions containing meropenem and assaying the resulting liquids. Erythromycin (25 11g/mL) or neomycin (5 ii,g/mL) did not interfere with the assay. However, addition of 10 to 25 pg of neomycin/mL did cause <1% interference. Clinical laboratory tests were conducted before and 48 hours after the operations to assess hematology, clinical chemistry, and urinalysis parameters. All data were analyzed by means of the SAS system (SAS Institute, Cary, NC) and the RS 1 software package (BBN Software Products Corporation, Cambridge, MA).
The concentration of meropenem in tissue specimens and body fluids was determined by using a standardized and validated well agar-diffusion assay with Escherichia coli, strain NIHJ, as the indicator of bioactivity; these assays were performed at Zeneca Pharmaceuticals Group. These assays typically detected 0.25 mg of meropenem/mL. When meropenem was added to extracts prepared from antibacterial-free tissue specimens and body fluids, recovery was > 80% (coefficient of variation, <8%).
Results
Sixty-six patients (average age, 47.9 years; 29 males: average weight, 73.7 kg; 37 females: average weight, 71.3 kg) treated at four centers received meropenem. Data for patients with minor protocol violations (5 patients weighed >200 lb, 1 patient weighted < 100 lb, 1 patient received metronidazole for bowel decontamination before the operation, 4 patients had serum creatinine levels of >1.5 mg/dL at enrollment, and 1 patient had a seizure history) were included in the analysis.
Collection times for plasma and tissue samples after the start of infusion ranged from 5 minutes to 9.5 hours and 5 minutes to 8 hours, respectively. Samples taken before 30 minutes (i.e., before the end of meropenem infusion) were not used in calculations of medians. Data are grouped into four broad intervals for presentation (table 1) .
Meropenem rapidly penetrated intraabdominal tissues, achieving concentrations above the MIC for 90% of intraabdominal pathogens within -1 hour after the start of dosing. The meropenem concentration in the peritoneal fluid sample obtained -1 hour after the start of dosing was 12.2 pg/mL, and the concentration in a sample obtained at -4 hours was 2 //g/mL. The meropenem concentration in the single stomach tissue sample obtained -1 hour after dosing was 2.8 //gig, and the concentrations in two specimens obtained at -2 hours averaged 0.9 //gig. Peak meropenem concentrations in bile and muscle specimens were achieved within -2 to -4 hours; hence, tissue levels of meropenem did not necessarily follow serum levels.
Twenty-three patients (35%) had a total of 46 adverse events; all events except for one report of nausea were considered by the investigator to be unrelated to meropenem. The most frequently reported adverse events (...-3 reports) were nausea (8), vomiting (6), and pruritus (3).
Discussion
Our study demonstrated that after administration of a single intravenous 1,000-mg dose of meropenem, adequate concentrations were achieved in tissue and fluid specimens tested to inhibit the growth of common intraabdominal pathogens (table  2) . Bile concentrations of meropenem approached peak plasma concentrations as time after administration of the dose increased (which is consistent with excretion of drug into bile), and meropenem concentrations in colon tissue samples were well above reported MICs for 90% of strains of aerobic and anaerobic fecal bacteria [5, 6] . High concentrations of meropenem in bile and colon tissues may be reflected positively in terms of clinical efficacy in treating infection. A lack of a major impact of meropenem on the intestinal microflora was reported by Bergen et al. [7] .
